Marta Figueiredo, PhD, managing science editor —

The Wyss Center for Bio and Neuroengineering is planning to launch a trial of its wireless brain computer interface (BCI), called ABILITY, in enabling people to communicate using only their thoughts. The study is expected to involve people in locked-in states — in which they are fully aware, but unable to…

Treating patients with their own immune regulatory T-cells (Tregs), in combination with IL-2 — a protein that boosts the cells’ immunosuppressive function and survival — is generally safe and shows potential to slow disease progression in people with amyotrophic lateral sclerosis (ALS). That’s according to a small Phase…

The cerebrospinal fluid of people with sporadic amyotrophic lateral sclerosis (sALS), but not of those with familial forms of the disease, promoted ALS-specific molecular, cellular, and motor abnormalities in healthy mice, a study showed. Apolipoprotein B-100 (apoB100), a protein involved in cholesterol transport, was identified as the main…

The European Medicines Agency (EMA) has agreed to review an application seeking the conditional approval of AB Science’s masitinib, now Alsitek, for the treatment of amyotrophic lateral sclerosis (ALS). Conditional approval is granted to a medication whose immediate availability fulfills an unmet medical need, when its preliminary benefits are…

A clinical trial is evaluating whether a new, implantable brain computer interface (BCI) is able to decode brain signals — ones research has shown are related to tasks relying on the hands or speech — and transform them into actions for people with neurological disease or injury. Up to 15…

Brainstorm Cell Therapeutics is preparing to file an application with the U.S. Food and Drug Administration (FDA) requesting approval of its cell-based therapy NurOwn for amyotrophic lateral sclerosis (ALS). The decision to submit a biologics license application was based on “the totality of the evidence from NurOwn’s clinical…

Note: This story was updated Aug. 10, 2022, to clarify the U.S. Food and Drug Administration advisory committee voted there is no substantial evidence supporting AMX0035 efficacy. When added to standard of care, both the experimental oral therapy AMX0035 and the U.S.-approved Radicava ORS oral suspension provide comparable…

NeuroSense Therapeutics has joined EverythingALS’s open innovation consortium to accelerate the development of treatments for amyotrophic lateral sclerosis (ALS). NeuroSense will provide financial support for ongoing research projects from the patient-focused nonprofit organization, such as those that seek to identify biological and digital biomarkers to help detect and monitor ALS.

Albrioza, an oral therapy for amyotrophic lateral sclerosis (ALS) still widely known as AMX0035, is now commercially available in Canada, its developer, Amylyx Pharmaceuticals, announced. Its market availability comes about 1.5 months after the therapy was conditionally approved by Health Canada for this neurodegenerative disease. The regulatory decision was based on…

The first patient has been dosed in an open-label Phase 2 trial that’s evaluating Seelos Therapeutics’ experimental therapy SLS-005 in people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases associated with the accumulation of toxic protein aggregates. Called a basket trial because it tests one therapy in…